Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of eltrombopag olamine 25 mg tablet versus Revolade in healthy Thai volunteers under fasting conditions
TCTR20261002007Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eltrombopag (2 arms), sponsored by International Bio Service. Primary endpoints: Maximum plasma concentration (Cmax), Area under the curve from time zero to last quantifiable concentration (AUC0-tlast) and 1 more. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
eltrombopag
Beyond the preview
Go deeper on TCTR20261002007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261002007.